Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.
Tags: COVID-19, Famotidine, Hydroxychloroquine
Reference: Early outpatient treatment of symptomatic, High-Risk Covid-19 patients that should be rampedup immediately as key to the pandemic crisis
More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that number carry antibodies to it.